211 
Market Cap
Stock Chart
GeneticTech - 30 Day Poll
Recent BLOGS About GeneticTech Add New
Latest Company News
|
Genetic Technologies Files Quarterly Activities Report and ASX Appendix 4C for ...
MarketWatch (press release) - Jan 31, 2012 MELBOURNE, AUSTRALIA, Jan 31, 2012 (MARKETWIRE via COMTEX) -- Genetic Technologies Limited /quotes/zigman/87198/quotes/nls/gene GENE -6.74% (asx:GTG) today announced it has filed its Quarterly Activities Report and Appendix 4C for period ending ...
|
|
Genetic Technologies Limited Executes Settlement And License Agreement
Reuters Key Development - Nov 30, 2011 |
|
Genetic Technologies Limited's ImmunAid Pty. Ltd. Announces Grant Of Patent In Europe
Reuters Key Development - Nov 1, 2011 |
|
Genetic Technologies Limited Not To Pay FY 2011 Final Dividend
Reuters Key Development - Aug 25, 2011 |
|
Genetic Technologies Limited Executes Settlement And License Agreement With Navigenics Inc.
Reuters Key Development - Jun 28, 2011 |
Website
Videos related to GeneticTech
Company Profile
Genetic Technologies (ASX: GTG, NASDAQ Global Market: GENE) is a genetic testing and reproductive services business which, together with a range of international patents and allied research activities, aims at uncovering the impact of DNA on health. The Company’s principal activities include the provision of genetic testing services and canine reproductive services.
Throughout the Asia Pacific region, they translate specialised genetic tests into products and services that optimise the health knowledge and outcomes in humans, animals and plants.
A strong patetnt position?
They have filed a patent infringement suits against nine U.S. biotechnology companies, including Bechman Coulter and Monsanto (Tier 1 organizsations). The patent at the centre of the suit refers to non-coding DNA technologies that Genetic Technologies claims are being used by the biotech firms without license. The counter-parties in the suit are Beckman Coulter, Orchid Cellmark, Gen-Probe, Interleukin Genetics, Molecular Pathology Laboratory Network, Monsanto, PIC USA, Sunrise Medical Laboratories and Pioneer Hi-Bred International. The non-coding DNA technology in question is already licensed to 39 other companies.
In 2008 Genetic Technologies stirred up controversy by demanding several Australian labs cease performing a test for the breast cancer genes BRCA1 and BRCA2 for which the company held an exclusive license. Genetic Technologies later withdrew the threat and allowed testing for the genes to continue. The company has been successful in other patent infringement suits, such as in 2005 against Applera Corporation (now ABI Biosystems).
Total revenue and income ($m)
2006: $10.39
2007: $10.76
2008: $15.32
2009: $15.98 (net loss after tax $7.86M)